Vanda puts anxiety drug’s development on ice after Phase III fail

Phase 3negativeNegative

AI Analysis

Summary

Vanda Pharmaceuticals has discontinued development of its anxiety drug following a Phase III trial failure for social anxiety disorder. The company joins multiple pharma peers struggling to innovate in the SAD treatment space.

Clinical Trial Data

Phase

Phase 3

Primary Endpoint

Not Met

Outcome Details

Phase III trial failed

Importance:6/10

Sentiment:

-0.80

Phase 3 failureSAD indicationdevelopment haltedanxiety disorder

Related Companies

$TRAX $ARNA

Read the original article

Published by Clinical Trials Arena on October 15, 2026 10:33 AM

Read Original